Because the numbers of B cells producing IgG and IgA were unaffected, one could suggest that a secondary vaccination response was observed, characterized by the activation of already existing influenza-specific memory B cells that had not been depleted by the RTX treatment. This evidence concerns the gene CD79A and influenza.